COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

FIrst-Pass Reperfusion With the NeVa Stent-Retriever Trial (FIRST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04072367
Recruitment Status : Withdrawn (The study was withdrawn due to a change in company strategy.)
First Posted : August 28, 2019
Last Update Posted : May 21, 2020
Information provided by (Responsible Party):

Brief Summary:
This study is designed to compare the safety, performance and efficacy of blood clot (thrombus) removal in subjects presenting with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Device: NeVa Stent Retrievers Device: Solitaire Stent Retrievers Not Applicable

Detailed Description:

A pivotal, randomized, open label, assessor-blinded, 90-day study designed to compare the safety, performance and efficacy of thrombus removal in subjects aged ≥ 18 years presenting with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.

A total of 414 eligible subjects will be randomized in a 1:1 ratio to one of two treatment groups:

  • Active Treatment Group
  • Control Device

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Open-Label, Multi-Center, Assessor-Blinded Study Designed to Compare the Safety, Performance and Efficacy of the NeVatm Stent Retriever Versus the Solitairetm Stent Retriever
Estimated Study Start Date : December 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Active Treatment Group
NeVa Stent Retrievers
Device: NeVa Stent Retrievers
thrombus removal

Control Device
Solitare Stent Retrievers
Device: Solitaire Stent Retrievers
thrombus removal

Primary Outcome Measures :
  1. Reperfusion rate [ Time Frame: post-procedure day 0 ]
    The primary study endpoint is the reperfusion rate of the occluded target vessel (defined by an eTICI score ≥ 2b) following one single pass using the assigned stent retriever device(s)

Secondary Outcome Measures :
  1. Stent retriever comparison [ Time Frame: Day 90 ]
    The secondary endpoint is the proportion of subjects treated with the NeVa device with good clinical outcomes at the Day 90 evaluation (defined as mRS score ≤ 2) when compared to the subjects treated with the predicate.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • A new focal disabling neurologic deficit consistent with acute cerebral ischemia
  • NIHSS score ≥ 6;
  • Prestroke mRS score of ≤ 2;
  • Angiographic confirmation by DSA of an occlusion (eTICI 0-1) of the intracranial ICA, MCA-M1, MCA-M2, basilar artery, or intracranial vertebral artery with or without tandem involvement of the cervical ICA or cervical vertebral artery;
  • Imaging Criteria:

    1. Strokes in the Anterior Circulation:

      • Non-Contrast CT (NCCT): ASPECTS 6 to 10 on baseline CT, or
      • CT perfusion (with Automated Volume Calculation): core infarct volume ≤ 70cc and Mismatch Ratio ≥ 1.5
      • CT perfusion (without Automated Volume Calculation): ASPECTS 6 to 10 on the CBV maps with Visualized MTT or TMax - CBV Mismatch greater than 50%, or
      • Brain MRI: ASPECTS 6 to 10 (and <70cc if Automated Volume Calculation is available) on baseline diffusion-weighted sequence (DWI).
    2. Strokes in the Posterior Circulation: pc-ASPECTS score 8 to 10 on baseline NCCT, CTA-source images, or DWI MRI.

      • Subjects for whom IV-tPA is indicated and who are available for treatment, are treated with IV-tPA within 4.5 hours of stroke onset (onset time is defined as the last time when the subject was witnessed to be at baseline), with verification that the subject has received/is receiving the correct IV t-PA dose for the estimated weight
      • Arterial puncture within 12 hours of symptom onset (or time last seen well - TLSW), thrombectomy procedure able to be completed within 2 hours from procedure start (arterial puncture).
      • Subject or legal representative is able and willing to give informed consent.

Exclusion Criteria:

  • Rapid neurological improvement prior to groin puncture suggestive of resolution of stroke
  • Seizures at stroke onset if it makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.

    • Note: Subjects with a questionable seizure at onset of stroke should not be excluded if DSA confirms the presence of intracranial ICA and/or M1 occlusion, and accurate NIHSS can be obtained.
  • Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
  • Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre-treatment pulmonary aspiration.
  • Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
  • Cerebral vasculitis.
  • History of severe allergy to contrast medium.
  • Known allergy to stent retriever materials (nitinol, stainless steel);
  • Suspicion of aortic dissection, septic embolus, or bacterial endocarditis.
  • Active infection.
  • Baseline CT or MRI showing mass effect or intracranial tumor (except small meningioma [≤ 3 cm]).
  • CT or MRI evidence of recent/fresh hemorrhage on presentation.
  • CTA, MRA, or DSA evidence of flow limiting carotid dissection, high-grade stenosis, or complete cervical carotid occlusion requiring stenting at the time of the index procedure (i.e., mechanical thrombectomy).
  • Evidence of dissection in the intracranial cerebral arteries;
  • Uncontrolled hypertension on presentation (defined as SBP > 220 mmHg and / or DBP > 120 mmHg). For subjects placed on intravenous BP medication, uncontrolled hypertension is defined as SBP > 185 mmHg and / or DBP > 110 mmHg.
  • Baseline hemoglobin of < 7 mmol/L.
  • Baseline platelet count < 50,000/uL.
  • Renal failure as defined by a serum creatinine >3.0 mg/dL (264 mmol/L).

    • Note: subjects on renal dialysis may be treated regardless of serum creatinine levels.
  • Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with INR > 3.0 or PTT > 3 times normal. Subjects on factor Xa inhibitor for 24-48 h ago must have a normal PTT.
  • Baseline blood glucose of < 50 mg/dL (2.78 mmol) or > 400 mg/dL (22.20 mmol). Note: The ''correction'' of baseline glucose or coagulation laboratory values to meet inclusion criteria will not be allowed.
  • Females who are pregnant or breastfeeding.
  • Known current or recent use of illicit drugs or alcohol abuse.
  • Use of an investigational drug or device within past 3 months;
  • Life expectancy less than 6 months.
  • Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04072367

Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Raul Gomes Nogueira, MD Emory University
Layout table for additonal information
Responsible Party: Vesalio Identifier: NCT04072367    
Other Study ID Numbers: VS-007
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes